Back to Search Start Over

Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments.

Authors :
Austin E
Huang A
Wang JY
Cohen M
Heilman E
Maverakis E
Michl J
Jagdeo J
Source :
Frontiers in oncology [Front Oncol] 2022 Jun 24; Vol. 12, pp. 928484. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Total annual cancer rates have decreased due to improved treatment and prevention. However, the incidence of melanoma is rising, and not all patients respond to immune and targeted approaches. Therefore, we sought to determine the efficacy of red light (RL) phototherapy in preclinical models of melanoma.<br />Methods: Melanoma cells (A375, B16F10, MNT-1) were irradiated with RL. Melanoma proliferation, apoptosis, oxidative stress, and p53 phosphorylation were measured in vitro . In C57BL/6 mice, phototherapy safety, B16F10 tumor growth, and immunocyte infiltration were assessed following RL.<br />Results: In vitro , 640 J/cm <superscript>2</superscript> RL decreased cellular proliferation without increasing apoptosis, while 1280 J/cm <superscript>2</superscript> increased apoptosis. RL increased intracellular reactive oxygen species generation and p53 phosphorylation. In animal models, 2560 J/cm <superscript>2</superscript> RL significantly prevented melanoma growth and increased the expression of CD103+ dendritic cells. 1280 and 1920 J/cm <superscript>2</superscript> RL decreased tumor volume, but not significantly. RL did not cause skin inflammation or erythema in normal skin.<br />Conclusion: RL represents a potentially safe and effective melanoma therapeutic. RL prevented tumor growth and increased the expression of immune markers, such as CD103, that are associated with favorable melanoma outcomes. Further research is needed to determine the optimal clinical treatment regimen for melanoma using RL.<br />Competing Interests: JJ is a consultant for GlobalMed Technologies (Omnilux). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Austin, Huang, Wang, Cohen, Heilman, Maverakis, Michl and Jagdeo.)

Details

Language :
English
ISSN :
2234-943X
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
35847848
Full Text :
https://doi.org/10.3389/fonc.2022.928484